Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ELYM NASDAQ:HILS NASDAQ:MRNS NYSE:NHWK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELYMEliem Therapeutics$1.51+3.4%$1.27$2.35▼$11.55$152.03M-0.39486,688 shs159,187 shsHILSHillstream BioPharma$1.69+2.4%$1.54$0.19▼$2.65$29.75M3.081.39 million shs70,516 shsMRNSMarinus Pharmaceuticals$0.55-0.2%$0.55$0.22▼$1.97$30.32M1.031.92 million shs260 shsNHWKNightHawk Biosciences$0.39$0.26▼$1.16$10.78M0.1997,242 shs173,100 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELYMEliem Therapeutics+3.42%+10.22%+22.76%+19.84%-77.96%HILSHillstream BioPharma+3.68%-2.31%+18.18%+49.57%-59.95%MRNSMarinus Pharmaceuticals0.00%0.00%0.00%0.00%-60.50%NHWKNightHawk Biosciences0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationELYMEliem TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AHILSHillstream BioPharmaN/AN/AN/AN/AN/AN/AN/AN/AMRNSMarinus Pharmaceuticals2.1041 of 5 stars3.20.00.04.20.01.70.6NHWKNightHawk BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceELYMEliem Therapeutics 0.00N/AN/AN/AHILSHillstream BioPharma 0.00N/AN/AN/AMRNSMarinus Pharmaceuticals 2.40Hold$3.92613.29% UpsideNHWKNightHawk Biosciences 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookELYMEliem TherapeuticsN/AN/AN/AN/A$3.90 per shareN/AHILSHillstream BioPharmaN/AN/AN/AN/A$0.48 per shareN/AMRNSMarinus Pharmaceuticals$30.99M0.98N/AN/A$0.31 per share1.77NHWKNightHawk Biosciences$6.38M0.00N/AN/A$2.82 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateELYMEliem Therapeutics-$35.12M-$0.53N/A∞N/AN/A-47.03%-45.97%N/AHILSHillstream BioPharma-$8.47M-$0.72N/AN/AN/AN/A-188.44%-149.61%N/AMRNSMarinus Pharmaceuticals-$141.40M-$2.47N/AN/AN/A-446.48%-7,831.35%-120.74%8/11/2025 (Estimated)NHWKNightHawk Biosciences-$43.44M-$1.99N/AN/AN/A-2,333.27%-91.62%-56.48%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthELYMEliem TherapeuticsN/AN/AN/AN/AN/AHILSHillstream BioPharmaN/AN/AN/AN/AN/AMRNSMarinus PharmaceuticalsN/AN/AN/AN/AN/ANHWKNightHawk BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioELYMEliem TherapeuticsN/A60.4160.41HILSHillstream BioPharmaN/A3.013.01MRNSMarinus PharmaceuticalsN/A1.661.47NHWKNightHawk Biosciences0.270.990.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipELYMEliem Therapeutics69.76%HILSHillstream BioPharma13.36%MRNSMarinus Pharmaceuticals98.80%NHWKNightHawk Biosciences21.16%Insider OwnershipCompanyInsider OwnershipELYMEliem Therapeutics4.70%HILSHillstream BioPharma30.24%MRNSMarinus Pharmaceuticals5.46%NHWKNightHawk Biosciences15.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableELYMEliem Therapeutics929.75 million28.35 millionNot OptionableHILSHillstream BioPharma117.60 million12.28 millionNot OptionableMRNSMarinus Pharmaceuticals11055.22 million52.20 millionOptionableNHWKNightHawk Biosciences7726.08 million21.94 millionOptionableNHWK, ELYM, MRNS, and HILS HeadlinesRecent News About These CompaniesIs NightHawk Biosciences Inc (NHWK) Stock a Good Investment?September 20, 2024 | aaii.comASCPXD Scorpius Holdings, Inc.July 20, 2024 | seekingalpha.comScorpius Holdings GAAP EPS of -$1.74April 29, 2024 | seekingalpha.comScorpius Holdings Awarded Contract in Excess of $1 Million with NIH-Funded Researcher at a Major UniversityMarch 19, 2024 | globenewswire.comScorpius Holdings Accepted as a Member of the US Government's BioMaP-ConsortiumMarch 14, 2024 | globenewswire.comScorpius Holdings, Inc. Announces Closing of Public OfferingMarch 12, 2024 | globenewswire.comScorpius Holdings, Inc. Announces Pricing of Public OfferingMarch 7, 2024 | globenewswire.comScorpius Holdings, Inc. Announces Proposed Public Offering of Common StockMarch 7, 2024 | globenewswire.comScorpius Holdings Estimates Greater than 375% Sequential Increase in Revenue for the Fourth Quarter of 2023 Compared to the Third Quarter of 2023March 7, 2024 | globenewswire.comScorpius Holdings Estimates Greater than 375% Sequential Increase in Revenue for the Fourth Quarter of 2023 Compared to the Third Quarter of 2023March 7, 2024 | globenewswire.comScorpius Holdings, Inc. (SCPX)February 13, 2024 | uk.finance.yahoo.comNightHawk Biosciences Debuts SCPX Ticker on NYSE AmericanFebruary 7, 2024 | msn.comNightHawk Biosciences Unveils New Name and TickerFebruary 7, 2024 | msn.comNightHawk Biosciences Strikes Key Licensing and Financing DealsJanuary 31, 2024 | msn.comNightHawk Receives Proceeds of $3.25 Million in Connection with Sale of Non-Core Intellectual Property and Issuance of a Low Interest Bearing NoteJanuary 30, 2024 | finance.yahoo.comNightHawk’s Scorpius BioManufacturing Subsidiary Awarded Multimillion- Dollar Contract with a ...January 25, 2024 | bakersfield.comBNightHawk’s Scorpius BioManufacturing Subsidiary Awarded Multimillion- Dollar Contract with a Publicly Traded Biotech Company to Support its Phase 2 Clinical ProgramJanuary 25, 2024 | finance.yahoo.comNightHawk Biosciences: NightHawk's Scorpius BioManufacturing Subsidiary Commences Work on Preclinical Program for New ClientJanuary 16, 2024 | finanznachrichten.deNightHawk’s Scorpius BioManufacturing Subsidiary Commences Work on Preclinical Program for New ClientJanuary 16, 2024 | finance.yahoo.comNHWK: Transformational ChangesJanuary 11, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNHWK, ELYM, MRNS, and HILS Company DescriptionsEliem Therapeutics NASDAQ:ELYM$1.51 +0.05 (+3.42%) As of 07/18/2025Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.Hillstream BioPharma NASDAQ:HILS$1.69 +0.04 (+2.42%) As of 07/18/2025Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) and targeted immuno-oncology novel biologics for the treatment drug resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-3215, an anti-HER2 monoclonal antibody candidate; and HSB-1940, a Quatrabody that is a proprietary IO biologic in development targeting PD-1. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.Marinus Pharmaceuticals NASDAQ:MRNSMarinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.NightHawk Biosciences NYSE:NHWKNightHawk Biosciences, Inc., an integrated biopharmaceutical company, develops, manufactures, and commercializes medical countermeasures that combat unmet and emerging biothreats. The company develops ANTHIM (obiltoxaximab), a monoclonal antibody antitoxin for the treatment of inhalational anthrax. The company was formerly known as Heat Biologics, Inc. and changed its name to NightHawk Biosciences, Inc. in May 2022. NightHawk Biosciences, Inc. was incorporated in 2008 and is based in Morrisville, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
